Immatics Advances Anzu-cel Phase 3 Program; Reports Q2 Revenue Growth
(RTTNews) - Immatics N.V. (IMTX), a global biopharmaceutical company focused on precision targeting of PRAME, provided a business update and reported second-quarter 2026 financial results, highlighting progress across its cell therapy and bispecific pipeline.
Immatics said enrollment in the Phase 3 SUPRAME trial of anzu-cel (anzutresgene autoleucel, IMA203) remains on track to complete the required randomizations by year-end.
The Phase 3 SUPRAME trial is evaluating patients with unresectable or metastatic cutaneous melanoma who progressed following prior PD-1 checkpoint inhibitor therapy, while PFS events are occurring more slowly than initially modeled.
The company plans to proceed directly to a streamlined final analysis of the primary PFS endpoint, while increasing statistical power for the secondary overall survival (OS) endpoint by enrolling approximately 90 additional patients.
The total trial size is expected to increase to approximately 450 patients.
Immatics expects to report topline data from the final PFS analysis in the first half of 2027, followed by a Biologics License Application (BLA) submission later in 2027.
Updated Phase 1b data for anzu-cel presented at ASCO 2026 continued to demonstrate durable anti-tumor activity in metastatic melanoma, with a 56% confirmed objective response rate (ORR), median duration of response of 14.6 months, median PFS of 6.1 months and median OS of 16.2 months.
The 12-month and 24-month OS rates were 70% and 46%, respectively.
Immatics is also advancing IMA203CD8, a PRAME-directed cell therapy designed for broader development across advanced PRAME-positive cancers.
Updated Phase 1 data showed a 63% ORR and 50% confirmed ORR in hard-to-treat gynecologic cancers, with additional data expected at the ESMO Congress 2026.
The company is developing IMA402, an off-the-shelf PRAME-directed TCR bispecific, across multiple cancer types and treatment settings.
Phase 1b data at the recommended Phase 2 dose range are expected to be presented at ESMO 2026.
Immatics has also initiated a Phase 1b combination cohort evaluating IMA402 with IMA401, its MAGEA4/8-directed bispecific, in squamous non-small cell lung cancer. First data from the combination study are expected in 2027.
In addition, Moderna and Immatics achieved a clinical milestone under their collaboration after the first patient was dosed in July 2026 in a trial evaluating mRNA-4200, a cancer antigen therapeutic candidate discovered through their collaboration. The milestone triggered a payment to Immatics.
For the second quarter of 2026, Immatics reported total revenue of $10.4 million, compared with $5.4 million in the prior-year period, primarily driven by increased collaboration activity.
Research and development expenses increased to $71.1 million from $51.4 million, mainly reflecting higher costs associated with advancing clinical programs, particularly the SUPRAME trial.
General and administrative expenses rose to $15.8 million from $14.6 million, primarily due to activities supporting the company's commercialization preparations.
Immatics reported a second-quarter net loss of $62.4 million or $0.46 per share, compared with a net loss of $70.3 million or $0.58 per share in the second quarter of 2025.
As of June 30, 2026, Immatics had $448.2 million in cash, cash equivalents and other financial assets. The company expects its cash resources to fund operations into 2028.
Immatics continues to build its commercial infrastructure for the anticipated launch of anzu-cel while advancing its broader PRAME franchise across cell therapies, bispecifics and combination approaches.
IMTX has traded between $5.05 and $12.41 over the past year. Currently, IMTX is trading at $9.08, down 1.84%.
